S455 Efficacy and Safety of the Selective Sphingosine 1-Phosphate Receptor Modulator, Etrasimod, in Adult Patients With Eosinophilic Esophagitis: Primary Results From the Phase 2 VOYAGE Study

S. Dellon, Evan; H. Collins, Margaret; J. Bredenoord, Albert; Philpott, Hamish; Biedermann, Luc; Dulcine, Márjori; Nguyen-Cleary, Thai; Su, Chinyu; Yu, Jin; Cataldi, Fabio; Zheng, Hanzhe; Wang, Wenjin; V. Springveld, Natalie; Woolcott, John; Hirano, Ikuo

doi:10.14309/01.ajg.0000951460.86738.5a

Public

S455 Efficacy and Safety of the Selective Sphingosine 1-Phosphate Receptor Modulator, Etrasimod, in Adult Patients With Eosinophilic Esophagitis: Primary Results From the Phase 2 VOYAGE Study

Published in The American Journal of Gastroenterology • Oct 1, 2023

Authors:

Evan S. Dellon

Margaret H. Collins

Albert J. Bredenoord

Abstract

Introduction: Etrasimod is an investigational, oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development to treat immune-mediated inflammatory disorders. Etrasimod regulates lymphocyte egress from secondary lymphatic organs, and therefore may have promise ...

View

Paywalled

Subject

Eosinophilic esophagitis

Medicine

Sphingosine-1-phosphate

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Subject

Generate AI Take for this paper

Discussions